Part, Chapter, Paragraph
1 I, 2. 4 | incidence and prevalence rates, treatment and cure rates, and access
2 I, 2. 4 | hypertension detection and treatment, surgical interventions
3 I, 2. 5 | indexation rules and the treatment of non contributory periods,
4 I, 2. 10. 3 | forms needed for health treatment in another Member State.
5 I, 2. 10. 4 | product manufacture to patient treatment, is imperative to comply
6 II, 5. 1. 1 | and within individuals. Treatment has become increasingly
7 II, 5. 1. 1 | patterns in time and different treatment. Certain medical conditions
8 II, 5. 1. 3 | the disease, prescribed treatment, care, hospital and other
9 II, 5. 1. 3 | understand the disease and the treatment, cooperate with health care
10 II, 5. 1. 3 | This is an integral part of treatment and care.~Therapeutic patient
11 II, 5. 1. 3 | self-managing or adapting the treatment to their particular chronic
12 II, 5. 1. 3 | families) to manage the treatment of their condition and prevent
13 II, 5. 2. 1 | make CVD prevention and treatment a priority to reduce the
14 II, 5. 2. 3 | behaviours, diagnosis and treatment.~The decline in mortality
15 II, 5. 2. 4 | healthy lifestyle and drug treatment for individuals at high
16 II, 5. 2. 4 | hypertension undergoing adequate treatment has not changed and is still
17 II, 5. 2. 5 | mainly smoking, whereas treatment of individuals including
18 II, 5. 2. 5 | the CVD risk increases; treatment targets for LDL cholesterol
19 II, 5. 2. 5 | life-long pharmacological treatment with drugs must be considered.~
20 II, 5. 2. 5 | suggests that improvements in treatment (thrombolysis; aspirin;
21 II, 5. 2. 6 | suggests that improvements in treatment (thrombolysis; aspirin;
22 II, 5. 2. 6 | high, a pharmacological treatment should be considered. All
23 II, 5. 2. 6 | antihypertensive classes available for treatment can be used, taking into
24 II, 5. 2. 6 | R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators (
25 II, 5. 2. 6 | of cholesterol-lowering treatment: prospective meta-analysis
26 II, 5. 2. 6 | risk factor: prevention and treatment. JAMA 275: 1571-1576.~Keys
27 II, 5. 2. 6 | Blood Pressure Lowering Treatment Trialists' Collaboration (
28 II, 5. 2. 7 | Education Program Adult Treatment Panel III Guidelines. J
29 II, 5. 3. 2 | providing comparative data about treatment patterns and outcomes, access
30 II, 5. 3. 2 | and outcomes, access to treatment between social groups. To
31 II, 5. 3. 2 | data, such as details on treatment, quality of life, hospitalisation
32 II, 5. 3. 2 | cancer screening and cancer treatment programmes:~· the EU should
33 II, 5. 3. 2 | inequality of access to treatment for cancer patients and
34 II, 5. 3. 6 | possibly related to advances in treatment. Moreover, it is important
35 II, 5. 3. 6 | availability of effective treatment (Coleman et al, 2003).~ ~
36 II, 5. 3. 6 | access to diagnostic and treatment facilities, tumour-site-specific
37 II, 5. 3. 7 | prevention, diagnosis and treatment, improving survival and
38 II, 5. 3. 7 | groups), to a more successful treatment of cancer patients due to
39 II, 5. 3. 7 | disease when too advanced for treatment, thus improve the quality
40 II, 5. 3. 7 | diagnosis, access to optimal treatment and investment in health
41 II, 5. 3. 7 | is well recognized in the treatment of several specific tumours
42 II, 5. 3. 7 | have been introduced in the treatment of metastatic cancer and
43 II, 5. 3. 7 | cancer and thus the cost of treatment is rapidly increasing when
44 II, 5. 3. 7 | most cost-effective cancer treatment.~ ~
45 II, 5. 3. 7 | early diagnosis, adequate treatment and end of life care. Organising
46 II, 5. 3. 7 | screening, early diagnosis and treatment, as well as research to
47 II, 5. 3. 7 | each patient’s diagnosis, treatment and support;~· Complex interventions
48 II, 5. 3. 7 | interventions for diagnosis or treatment require all the necessary
49 II, 5. 3. 7 | care for diagnosis and/or treatment at primary, secondary and
50 II, 5. 3. 7 | early detection, diagnosis, treatment and follow-up, and palliative
51 II, 5. 3. 8 | each requiring a different treatment.~These are the problems
52 II, 5. 3. 8 | in modern diagnostic and treatment technologies to eliminate
53 II, 5. 3. 8 | to cancer diagnosis and treatment facilities in Europe (especially
54 II, 5. 3. 8 | Give the best possible treatment and care to cancer patients,
55 II, 5. 3. 8 | practices regarding diagnosis, treatment, rehabilitation and palliative
56 II, 5. 3. 8 | requiring each a different treatment. The long term objective
57 II, 5. 4. 1 | prevention, diagnosis and treatment of diabetes at national
58 II, 5. 4. 2 | prevention, identification and treatment of diabetes and particularly
59 II, 5. 4. 2 | includes patients receiving a treatment or having been hospitalised.~
60 II, 5. 4. 2 | subjects who received laser treatment<3 months after diagnosis
61 II, 5. 4. 2 | Indicator on timely laser treatment of retinopathy is defined
62 II, 5. 4. 2 | retinopathy and had laser treatment within 3 months.~Control
63 II, 5. 4. 3 | was in Scotland where the treatment of elevated cholesterol
64 II, 5. 4. 3 | Indicator on timely laser treatment of retinopathy. For this
65 II, 5. 4. 4 | on retinopathy and laser treatment scarcely available, flagging
66 II, 5. 4. 6 | obtained through intensive treatment from the moment of diagnosis
67 II, 5. 4. 6 | intervention (early intensive treatment) can modify the progression
68 II, 5. 4. 6 | self-education are a separate part of treatment and care for people with
69 II, 5. 4. 6 | prevention, diagnosis and treatment of diabetes in line with
70 II, 5. 4. 7 | to screening, diagnosis, treatment and care. Diabetes, like
71 II, 5. 4. 7 | processes, measurement done, treatment, management);~· population (
72 II, 5. 4. 8 | 2 diabetes. Occurrence, treatment and prevention seen in a
73 II, 5. 5.Int | hospitals for short term treatment. There are still many countries
74 II, 5. 5.Int | risk factors, detection and treatment and preliminary evidence
75 II, 5. 5.Int | awareness and better access to treatment options are necessary to
76 II, 5. 5.Int | lives, needing constant treatment. This creates distress for
77 II, 5. 5.Int | prevented through adequate treatment of psychiatric disorders
78 II, 5. 5.Int | and earlier detection and treatment of psychiatric illnesses
79 II, 5. 5.Int | the general population. Treatment with medications for depression,
80 II, 5. 5. 1 | about half receive adequate treatment (Alonso et al., 2004b).
81 II, 5. 5. 1 | quality of life, use of treatment and healthcare services.
82 II, 5. 5. 1 | Prevalence, incidence, access to treatment and work days lost in mood
83 II, 5. 5. 1 | and low accessibility to treatment were reported to be the
84 II, 5. 5. 1 | reported to be the hurdles in treatment of depression (European
85 II, 5. 5. 1 | 2008). Disability and treatment of specific mental and physical
86 II, 5. 5. 2 | diagnosis and appropriate treatment is needed in order to ensure
87 II, 5. 5. 2 | guidelines on diagnosis, treatment and psycho-social interventions,
88 II, 5. 5. 2 | improve the diagnosis and treatment of Alzheimer’s disease and
89 II, 5. 5. 3 | Health care providers report treatment attendance data (number
90 II, 5. 5. 3 | Health Insurance Centre (treatment attendance data) and in
91 II, 5. 5. 3 | gap between the need for treatment of schizophrenia and access
92 II, 5. 5. 3 | access or utilization of treatment which is connected with
93 II, 5. 5. 3 | functioning in the workplace.~Treatment and treatment gaps~During
94 II, 5. 5. 3 | workplace.~Treatment and treatment gaps~During the past decades,
95 II, 5. 5. 3 | significant advances in the treatment of schizophrenia. Medications (
96 II, 5. 5. 3 | aged > 15 , the regional treatment gap (median untreated rate =
97 II, 5. 5. 3 | inadequacy or unavailability of treatment, people with schizophrenia
98 II, 5. 5. 3 | schizophrenia exceeds the direct treatment costs due to remarkable
99 II, 5. 5. 3 | associated with schizophrenia, on treatment gaps and costs to cover
100 II, 5. 5. 3 | estimates based on first treatment/admission data due to the
101 II, 5. 5. 3 | taking into account the treatment gap, the evidence for coding
102 II, 5. 5. 3 | and Belgamwar 2006).~The treatment of people with co-morbid
103 II, 5. 5. 3 | frequent relapses, show poor treatment compliance and are difficult
104 II, 5. 5. 3 | underestimated.~Evidence based treatment of schizophrenia and treatment
105 II, 5. 5. 3 | treatment of schizophrenia and treatment gaps.~Treatment options~
106 II, 5. 5. 3 | schizophrenia and treatment gaps.~Treatment options~The state of the
107 II, 5. 5. 3 | state of the art of the treatment of schizophrenia comprises
108 II, 5. 5. 3 | behavioural therapy. For other treatment approaches, the authors
109 II, 5. 5. 3 | Besides optimizing the treatment of patients with schizophrenia,
110 II, 5. 5. 3 | diagnosed and appropriate treatment installed (Häfner et al,
111 II, 5. 5. 3 | develop. Besides, delayed treatment is more likely to be associated
112 II, 5. 5. 3 | strategies are needed for both, treatment of prodromal syndromes and
113 II, 5. 5. 3 | Although a number of prodromal treatment programmes have been initiated
114 II, 5. 5. 3 | literature review on the treatment gap in mental health care,
115 II, 5. 5. 3 | number of people needing treatment for schizophrenia and the
116 II, 5. 5. 3 | number of people receiving treatment calculated on service utilization
117 II, 5. 5. 3 | examination of the extent of the treatment gap in mental health care (
118 II, 5. 5. 3 | treatments exist), the median treatment gap for schizophrenia (including
119 II, 5. 5. 3 | receive timely and adequate treatment. This may lead to an increased
120 II, 5. 5. 3 | schizophrenia and in its treatment have led to the availability
121 II, 5. 5. 3 | from advances achieved in treatment and basic research. Reasons
122 II, 5. 5. 3 | plenty of evidence that the treatment of schizophrenia should
123 II, 5. 5. 3 | variability and its effect on treatment. Therefore, there is a need
124 II, 5. 5. 3 | factor responsible for a treatment gap is the non-compliance
125 II, 5. 5. 3 | within the EUFEST trial, treatment discontinuation over 12
126 II, 5. 5. 3 | than in those assigned to treatment with second-generation antipsychotic
127 II, 5. 5. 3 | insight into the necessity of treatment leads to discontinuation
128 II, 5. 5. 3 | guidelines on schizophrenia treatment, most of them do not meet
129 II, 5. 5. 3 | knowledge about schizophrenia treatment and to provide an algorithm
130 II, 5. 5. 3 | misallocation may lead to a treatment gap as demonstrated in the
131 II, 5. 5. 3 | findings on unmet needs for treatment among serious cases were
132 II, 5. 5. 3 | care. However, insufficient treatment is not merely a result of
133 II, 5. 5. 3 | 2004). While the need for treatment in cases of severe disorders
134 II, 5. 5. 3 | symptoms emerge and the delayed treatment even after onset of the
135 II, 5. 5. 3 | institutions that provide treatment, psychotropic drugs and
136 II, 5. 5. 3 | cost-effectiveness of current and optimal treatment for schizophrenia (Andrews
137 II, 5. 5. 3 | could be averted by optimal treatment compared to 13% with current
138 II, 5. 5. 3 | affordability of optimal treatment within present budgets.~
139 II, 5. 5. 3 | of unbiased schizophrenia treatment recommendations. In countries
140 II, 5. 5. 3 | for optimal comprehensive treatment.~There are reasons for being
141 II, 5. 5. 3 | achievements and future progress in treatment and in basic research, and
142 II, 5. 5. 3 | evaluation of psycho-social treatment strategies, and further
143 II, 5. 5. 3 | delivery of state-of-the-art treatment in all medical settings;~·
144 II, 5. 5. 3 | barriers towards optimal treatment;~· overcome stigma;~· ensure
145 II, 5. 5. 3 | Cost-effectiveness of current and optimal treatment for schizophrenia. Br J
146 II, 5. 5. 3 | severity, and unmet need for treatment of mental disorders in the
147 II, 5. 5. 3 | Saraceno B (2004): The treatment gap in mental health care.
148 II, 5. 5. 3 | best practices: current treatment guidelines and protocols
149 II, 5. 5. 3 | Evidence-based psychosocial treatment practices in schizophrenia:
150 II, 5. 5. 3 | Interventions in Long-term Treatment in Schizophrenia. psychoneuro
151 II, 5. 5. 3 | severity, and unmet need for treatment of mental disorders in the
152 II, 5. 5. 3 | the effectiveness of their treatment~ ~
153 II, 5. 5. 3 | Epilepsy in remission with treatment is defined by the absence
154 II, 5. 5. 3 | Epilepsy in remission without treatment (terminal remission) is
155 II, 5. 5. 3 | of whom immediately after treatment initiation (Forsgren, 2004).
156 II, 5. 5. 3 | preceding 5 years regardless of treatment with AEDs (Commission, 1993).
157 II, 5. 5. 3 | epilepsy undergoing surgical treatment (Harris & Barraclough, 1997).
158 II, 5. 5. 3 | complicated and unstable treatment (Jallon, 2004). SUDEP is
159 II, 5. 5. 3 | schizophrenia (PR 5.8).~ ~Prognosis~Treatment of epilepsy is generally
160 II, 5. 5. 3 | idiopathic (3-6 months)~ Treatment stop (ban 3 months)~ II
161 II, 5. 5. 3 | partial seizures (3 months)~ Treatment stop/change (ban 3 months)~
162 II, 5. 5. 3 | aspects of the diagnosis and treatment of epilepsy, these instruments
163 II, 5. 5. 3 | guidelines on the diagnosis and treatment of epilepsy should be disseminated
164 II, 5. 5. 3 | Aetiology of epilepsy. In: The Treatment of Epilepsy (2nd edition) (
165 II, 5. 5. 3 | prognosis of epilepsy and its treatment. In: The Treatment of Epilepsy (
166 II, 5. 5. 3 | and its treatment. In: The Treatment of Epilepsy (2nd edition). (
167 II, 5. 5. 3 | 2001): The dynamics of drug treatment in epilepsy: an observational
168 II, 5. 5. 3 | 10 is death due to MS.~ ~Treatment~There is no cure for MS,
169 II, 5. 5. 3 | evidence, early, aggressive treatment is warranted in all patients
170 II, 5. 5. 3 | and there is evidence that treatment with interferon beta has
171 II, 5. 5. 3 | is sometimes used for the treatment of worsening forms of RR-
172 II, 5. 5. 3 | Framework Directive on Equal Treatment in the Work Place~ ~Council
173 II, 5. 5. 3 | Framework Directive on equal treatment in the work place is an
174 II, 5. 5. 3 | effects of discriminatory treatment towards people with MS in
175 II, 5. 5. 3 | effects of discriminatory treatment towards people with multiple
176 II, 5. 5. 3 | Equal rights and access to treatment, therapies and services
177 II, 5. 5. 3 | inequalities in the diagnosis, treatment and care of people with
178 II, 5. 5. 3 | for example when a new treatment becomes available.~· Escalating
179 II, 5. 5. 3 | provide new data on the treatment of clinically isolated syndromes,
180 II, 5. 5. 3 | dealing with symptomatic treatment, high quality studies are
181 II, 5. 5. 3 | Consensus paper includes treatment guidelines for some of the
182 II, 5. 5. 3(26)| effects of discriminatory treatment made to people with multiple
183 II, 5. 5. 3 | seeks to enhance equity of treatment, access thereto and quality
184 II, 5. 5. 3 | approaches towards the diagnosis, treatment and management of MS. More
185 II, 5. 5. 3 | the European Committee in Treatment and Research in Multiple
186 II, 5. 5. 3 | Toyka KY (2006): Symptomatic Treatment of Multiple Sclerosis. Multiple
187 II, 5. 5. 3 | pharmacological and surgical treatment options available, the disease
188 II, 5. 5. 3 | least 17 years of levodopa treatment (Uitti et al, 1993).~ ~Comorbidity~
189 II, 5. 5. 3 | healthy population. Although treatment options for PD have increased
190 II, 5. 5. 3 | aspects of the diagnosis and treatment of PD, these instruments
191 II, 5. 5. 3 | not receive appropriate treatment. Identifying these individuals
192 II, 5. 6. 2 | guide to the prevention and treatment of musculoskeletal conditions
193 II, 5. 6. 3 | earliest stage to allow early treatment. Recently, recommendations
194 II, 5. 6. 3 | Course, 2008).~ ~Modern treatment is effective in controlling
195 II, 5. 6. 3 | long-term disability. Early treatment aimed at controlling disease
196 II, 5. 6. 3 | aggressive approaches towards treatment with less effective therapeutic
197 II, 5. 6. 3 | current therapies. Modern treatment is effective at controlling
198 II, 5. 6. 3 | disability, whilst early treatment aimed at controlling disease
199 II, 5. 6. 4 | Europeans under long-term treatment give as major reason muscle,
200 II, 5. 6. 6 | and medical perceptions of treatment in eight European countries.
201 II, 5. 7. 1 | undisputable evidence that treatment can prevent or delay kidney
202 II, 5. 7. 1 | 73 m2 )~ICD 9 CM Code~ ~Treatment~ ~1~Kidney damage~with normal
203 II, 5. 7. 2 | patients the changes in treatment and the date and cause of
204 II, 5. 7. 3 | investigators to suggest that treatment strategies for the prevention
205 II, 5. 7. 3 | investigators to suggest that treatment strategies for the prevention
206 II, 5. 7. 5 | drugs should be used for the treatment of neoplasia, screening
207 II, 5. 7. 5 | reporting on quality of treatment is still not compulsory.~·
208 II, 5. 7. 5 | potentially life-saving advice and treatment. CKD receives 27 points
209 II, 5. 7. 5 | concerning the provision of ESRD treatment throughout Austria have
210 II, 5. 7. 5 | quality assurance in ESRD treatment. The Health Plan found its
211 II, 5. 7. 5 | were 464 pmp under dialysis treatment. The registry of patients (
212 II, 5. 7. 6 | patients, whereas costs of treatment are lower, it is important
213 II, 5. 7. 7 | albuminuria and subsequent treatment with an ACE inhibitor to
214 II, 5. 7. 7 | Detection, Evaluation, and Treatment of High Blood Pressure:
215 II, 5. 7. 7 | Detection, Evaluation, and Treatment of High Blood Pressure OQI
216 II, 5. 8. 3 | impact or require different treatment for patients with COPD (
217 II, 5. 8. 3 | considering the total cost for treatment of 40+ year patients, 10%
218 II, 5. 8. 3 | patients, 10% was directed to treatment of COPD (Bilde et al, 2007).
219 II, 5. 8. 3 | these costs were due to the treatment of COPD as primary diagnosis,
220 II, 5. 8. 3 | 37 days and the cost of treatment per patient was 1.017 Euro.
221 II, 5. 8. 3 | length of stay, cost of treatment) were higher for COPD than
222 II, 5. 8. 7 | Standards for the diagnosis and treatment of patients with COPD: a
223 II, 5. 8. 7 | from hospital: the role of treatment and co-morbidity. Respir
224 II, 5. 9. FB | thus, prompt diagnosis and treatment are required to stop the
225 II, 5. 9. FB | do not receive adequate treatment. Allergic diseases are considered “
226 II, 5. 9. FB | problem of diagnosis and treatment compliance by health professionals
227 II, 5. 9. FB | effective diagnosis and treatment. Prevention requires a more
228 II, 5. 9. FB | better implementation of treatment guidelines requires more
229 II, 5. 9. FB | individuals to begin an early treatment. In Europe,,allergic patients
230 II, 5. 9. 1 | spontaneously or following treatment. AR is associated with impairments
231 II, 5. 9. 1 | combined diagnostic and treatment strategy should be used
232 II, 5. 9. 3 | diagnosis, 25100 received treatment from general practitioner,
233 II, 5. 9. 3 | whilst emergency room treatment was 14-18%. Nevertheless,
234 II, 5. 9. 3 | 85 days and the cost of treatment per patient was 750.18 Euro (
235 II, 5. 9. 3 | length of stay, cost of treatment) was higher for COPD than
236 II, 5. 9. 5 | guidelines for diagnosis and treatment of proven efficacy. Prevention
237 II, 5. 9. 5 | better implementation of treatment guidelines requires more
238 II, 5. 9. 5 | methods of diagnosis and treatment strategies. The emphasis
239 II, 5. 9. 5 | gain a better awareness of treatment targets.~New anti-allergic
240 II, 5. 9. 5 | and for a final diagnosis, treatment and clinical monitoring
241 II, 5. 9. 6 | the choice of appropriate treatment (WHO, 1952).~ ~GINA guidelines
242 II, 5. 9. 6 | worldwide for what concerns treatment and evidence-based recommendations (
243 II, 5. 9. 6 | rhinitis and make effective treatment for rhinitic symptoms available
244 II, 5. 10. 4 | beyond the cost of diagnosis, treatment of clinical manifestations,
245 II, 5. 10. 7 | approaches to diagnosis and treatment of celiac disease: An evolving
246 II, 5. 11. 3 | regarding the most appropriate treatment that can prevent lifelong
247 II, 5. 11. 6 | could, in turn, improve treatment and lead to a more effective
248 II, 5. 12. 3 | endoscopic banding, drug treatment and transjugular intraheatic
249 II, 5. 12. 6 | a contribution towards treatment and prognosis of cirrhosis
250 II, 5. 12. 6 | increase its role in the treatment and prognosis of cirrhosis,
251 II, 5. 14. 1 | rates and more unmet dental treatment needs than their higher
252 II, 5. 14. 3 | rates and more unmet dental treatment needs than their higher
253 II, 5. 14. 3 | same populations for whom treatment is apparently difficult
254 II, 5. 14. 6 | professionals and limiting treatment costs have also to be taken
255 II, 5. 14. 7 | missing teeth. Prosthetic treatment is not uniquely limited
256 II, 5. 14. 7 | practice in dentistry and treatment decision making is absolutely
257 II, 5. 15. 4 | prevention, diagnosis and treatment of RD and to provide a forum
258 II, 5. 15. 4 | prevention, diagnosis, treatment, care, and research for
259 II, 5. 15. 5 | access for EU citizens to treatment requiring a particular concentration/
260 II, 6. 3. 1 | hospital-acquired infection treatment are included. Also, a recent
261 II, 6. 3. 3 | access to antiretroviral treatment likely to be less than in
262 II, 6. 3. 3 | need to receive life-long treatment, care and support. Currently
263 II, 6. 3. 4 | infectious patients and treatment for at least six months
264 II, 6. 3. 4 | antibiotics. Inadequate treatment may result in failure of
265 II, 6. 3. 6 | do not require any drug treatment, invasive infections do
266 II, 6. 3. 7 | health concern in Europe. No treatment or vaccine is currently
267 II, 6. 3. 7 | ticks. There is no specific treatment or vaccine available, and
268 II, 6. 3. 7 | blood or body fluids. No treatment or vaccine is available
269 II, 6. 3. 7 | for the virus. No specific treatment is available for yellow fever,
270 II, 6. 4. 5 | dose and duration of the treatment and training on hygiene
271 II, 7. 3. 1 | 18 300 000 Other medical Treatment~ ~· This corresponds to
272 II, 7. 4. 2 | elderly will receive medical treatment due to an injury each year,
273 II, 7. 6 | improvements of medical treatment ( e.g. trauma and emergency
274 II, 8. 1. 5 | right to dignity, equal treatment, independent living and
275 II, 8. 2. 1 | conditions do not begin treatment soon after birth. Parents
276 II, 8. 2. 1 | those who received standard treatment alone. They suggest that
277 II, 8. 2. 1 | identification of disease and treatment availability contribute
278 II, 8. 2. 1 | special diet. If the correct treatment is started soon enough after
279 II, 8. 2. 2 | direct costs are those of the treatment of eye diseases, including
280 II, 9 | primary prevention as well. Treatment effects appear to be similar
281 II, 9. 1. 1 | pregnancies following fertility treatment~R: Distribution of timing
282 II, 9. 1. 1 | a detailed and specific treatment of congenital malformations.~ ~
283 II, 9. 1. 2 | concerns access to preventive treatment and rehabilitative research,
284 II, 9. 1. 2 | pregnancy d) the quality of treatment for congenital anomalies (
285 II, 9. 2. 2 | and to facilities for the treatment of illness and rehabilitation
286 II, 9. 2. 3(2) | diagnostic labelling and treatment by doctors between populations.
287 II, 9. 2. 3 | system in order to close the treatment gap in this area. The EU
288 II, 9. 3. 1 | best form of diagnosis and treatment. For instance, erectile
289 II, 9. 3. 1 | risk factors, detection, treatment and preliminary evidence
290 II, 9. 3. 1 | hospitals for short term treatment. There are still many countries
291 II, 9. 3. 1 | lives, needing constant treatment. This creates distress for
292 II, 9. 3. 1 | for further testing and treatment (Arber, 2006).~ ~Because
293 II, 9. 3. 1 | diagnosed by ultrasound scan and treatment has a high success rate.
294 II, 9. 3. 1 | with diabetes under medical treatment grew by 43% from 1988 to
295 II, 9. 3. 1 | more effective than drug treatment in reducing the incidence
296 II, 9. 3. 1 | which may influence the treatment and severity of the health
297 II, 9. 3. 1 | in patient selection for treatment or intervention for osteoporosis,
298 II, 9. 3. 1 | individuals at greatest need for treatment still remains a problem.
299 II, 9. 3. 1 | osteoporosis and may not receive treatment to prevent further loss
300 II, 9. 3. 1 | fractures and their (surgical) treatment being considerably greater
301 II, 9. 3. 1 | undergoing glucocorticoid steroid treatment for lung disease (Lim &
302 II, 9. 3. 1 | Fitzpatrick, 2004); the treatment of prostate cancer, which
303 II, 9. 3. 1 | initiating Androgen Replacement Treatment (ART). In case of unclear
304 II, 9. 3. 1 | primary prevention as well. Treatment effects appear to be similar
305 II, 9. 3. 1 | Advances in Psychiatric Treatment 14: 256-262~ ~Braun, M.,
306 II, 9. 3. 1 | gonadotropin-releasing hormone agonist treatment for prostate carcinoma.
307 II, 9. 3. 2 | Infertility and treatment of infertility~Advances
308 II, 9. 4. 3 | awareness and better access to treatment options are needed to prevent,
309 II, 9. 4. 3 | more effective forms of treatment for CHD, leading to more
310 II, 9. 4. 3 | Possible causes are that treatment is not as good as that given
311 II, 9. 4. 3 | may not tolerate intensive treatment, or doctors do not focus
312 II, 9. 5. 1 | history, diagnosis, and treatment of disease between men and
313 II, 9. 5. 1 | risk factors, symptoms and treatment of cardiovascular diseases
314 II, 9. 5. 1 | not receive as effective treatment or health information as
315 II, 9. 5. 1 | respond differently to the treatment they receive. Most research
316 II, 9. 5. 1 | Research on the types of treatment that are best for women
317 II, 9. 5. 3 | access to screening and treatment, may adversely influence
318 II, 9. 5. 3 | bias can also occur in the treatment of psychological disorders.
319 II, 9. 5. 3 | 30 000). In comparison, treatment for the perpetrator costs
320 II, 9. 5. 3 | problem drinkers receiving treatment cite marital conflict as
321 II, 9. 5. 3 | support rather than the treatment per se. Women are more likely
322 II, 9. 5. 4 | opportunities and equal treatment of men and women in matters
323 III, 10. 1. 3 | alcohol use, alcoholism treatment, and relapse. Alcohol Res
324 III, 10. 1. 3 | 1994): The diagnosis and treatment of social phobia and alcohol
325 III, 10. 2. 1 | the costs linked to the treatment of reproductive problems,
326 III, 10. 2. 1 | phases of tobacco addiction treatment, not only as a first-line
327 III, 10. 2. 1 | wide range of psychosocial treatment options, including counselling
328 III, 10. 2. 1 | to raise awareness about treatment possibilities.~ ~Curbing
329 III, 10. 2. 1 | information, warning labels and treatment for those wanting to quit
330 III, 10. 2. 1 | warnings and tobacco dependence treatment subscales was recorded.
331 III, 10. 2. 1 | warning labels (5) and treatment for those wanting to quit
332 III, 10. 2. 1 | alcohol-related. Alcohol alters the treatment course of injured patients
333 III, 10. 2. 1 | licensed premises.~ ~Advice and treatment~ ~Healthcare-based interventions
334 III, 10. 2. 1 | wide variety of specialized treatment approaches have been evaluated,
335 III, 10. 2. 1 | than those not receiving treatment. Moreover, for the average
336 III, 10. 2. 1 | Genomics, mechanism and treatment of addiction~http ~ ~European
337 III, 10. 2. 1 | Drugs and Drug Addiction~TDI~Treatment demand indicator~ ~ ~
338 III, 10. 2. 1 | users; (v) demand for drug treatment), but also other important
339 III, 10. 2. 1 | drug-related problems (prevention, treatment, harm reduction, etc.),
340 III, 10. 2. 1 | problem drug users (PDUs), treatment demands and drug overdoses
341 III, 10. 2. 1 | frequently a complication for treatment.~ ~Morbidity: HIV & Hepatitis
342 III, 10. 2. 1 | near future and access to treatment will be a critical issue.~ ~
343 III, 10. 2. 1 | the last reporting year.~ ~Treatment demand17~ ~In many countries,
344 III, 10. 2. 1 | the main drug for which treatment is seeked. Of the total
345 III, 10. 2. 1 | total approximately 326 000 treatment requests reported in 2005,
346 III, 10. 2. 1 | the relative proportion of treatment demands made by non-opioid
347 III, 10. 2. 1 | clients is increasing in the Treatment Demand Indicator (TDI) data
348 III, 10. 2. 1 | of new clients demanding treatment for opioid use has been
349 III, 10. 2. 1 | new drugs clients seeking treatment went down from 64% to 32%.
350 III, 10. 2. 1 | proportion of clients seeking treatment for primary cannabis use
351 III, 10. 2. 1 | the reason for entering treatment in Europe. From 1999 to
352 III, 10. 2. 1 | of new clients demanding treatment for cocaine use more than
353 III, 10. 2. 1 | data on drug users entering treatment for primary cocaine use
354 III, 10. 2. 1 | overall number of demands for treatment related to the use of amphetamines
355 III, 10. 2. 1 | reason for attending drug treatment in the EU.~ ~Figure 10.2.
356 III, 10. 2. 1 | of new clients entering treatment, subdivided by primary drug
357 III, 10. 2. 1(17)| methodological information about ‘Treatment Demand Indicator’ please
358 III, 10. 2. 1 | demand reduction (prevention, treatment and harm reduction) interventions
359 III, 10. 2. 1 | outpatient substitution treatment and harm reduction interventions
360 III, 10. 2. 1 | received drug substitution treatment in the EU Member States
361 III, 10. 2. 1 | coverage of substitution treatment could be made19, results
362 III, 10. 2. 1 | opiate users undergoing such treatment. Substitution treatment
363 III, 10. 2. 1 | treatment. Substitution treatment adds to other types of treatments
364 III, 10. 2. 1 | inpatient and outpatient treatment and detoxification. Social
365 III, 10. 2. 1 | interventions (prevention, treatment, social rehabilitation,
366 III, 10. 2. 1 | studied and prevention, treatment and harm reduction intervention
367 III, 10. 2. 1 | have developed accurate treatment modalities and assistance
368 III, 10. 2. 1 | among drug users, long-term treatment outcomes and other subjects
369 III, 10. 2. 1 | integrated prevention and treatment of chronic non-communicable
370 III, 10. 2. 1 | prevention, diagnosis and treatment of nutrition-related diseases).~·
371 III, 10. 2. 3 | high, a pharmacological treatment must be considered. Desired
372 III, 10. 3. 2 | and communal waste water treatment plants, recycling, and (
373 III, 10. 3. 2 | difference is due to obligatory treatment of furniture in the UK with
374 III, 10. 3. 3 | do not require any drug treatment, invasive infections do
375 III, 10. 3. 4 | improved prevention and treatment of winter infections have
376 III, 10. 3. 4 | surveillance, water analysis and treatment, health education and information
377 III, 10. 4. 1 | materials, chemicals from treatment of furniture and decorations,
378 III, 10. 4. 2 | polyacrylamide is used in wastewater treatment and paper and pulp processing.
379 III, 10. 4. 3 | quality control and water treatment mechanism is in place and
380 III, 10. 4. 3 | systems including water treatment and quality control. However,
381 III, 10. 4. 3 | usually consumed without any treatment.~ ~In certain parts of the
382 III, 10. 4. 3 | systems including water treatment and quality control. In
383 III, 10. 4. 3 | without any purification treatment. For example, in a sparsely
384 III, 10. 4. 3 | at http ~ ~Waste water treatment~ ~The European Union is
385 III, 10. 4. 3 | connected to wastewater treatment facilities between 1980
386 III, 10. 4. 3 | connected to wastewater treatment facilities in 2003. There
387 III, 10. 4. 3 | connected to wastewater treatment facilities. In Southern
388 III, 10. 4. 3 | connected to wastewater treatment facilities, selected European
389 III, 10. 4. 3 | contamination through appropriate treatment processes and the prevention
390 III, 10. 4. 3 | Waste water and waste water treatment is regulated by EU Council
391 III, 10. 4. 3 | discharges from urban waste water treatment plants to sensitive areas
392 III, 10. 4. 3 | insufficient waste water treatment. New potential pollutants
393 III, 10. 4. 3 | Current sewage and waste water treatment processes are not designed
394 III, 10. 4. 3 | with monitoring and local treatment at household level significantly
395 III, 10. 4. 5 | investments in waste water treatment facilities, bathing water
396 III, 10. 4. 5 | due to inadequate sewage treatment and pollution from animal
397 III, 10. 4. 5 | due to inadequate sewage treatment and pollution from animal
398 III, 10. 4. 5 | inadequate disposal and treatment of municipal and industrial
399 III, 10. 4. 5 | inappropriate disposal and treatment of waste from municipal
400 III, 10. 4. 5 | are in need of remedial treatment. These estimates have increased
401 III, 10. 4. 5 | activities, as well as the treatment and disposal of waste, remain
402 III, 10. 4. 5 | or exported for proper treatment.~ ~References~ ~European
403 III, 10. 5. 1 | requiring uninterrupted treatment such as TB and HIV are often
404 III, 10. 6. 1 | health promotion, prevention and treatment measures.~ ~
405 III, 10. 6. 2 | hypertension detection and treatment, surgical interventions
406 III, 10. 6. 2 | incidence and prevalence rates, treatment and cure rates, and access
407 IV, 11. 1. 1 | disease prevention and treatment, and quality of life of
408 IV, 11. 1. 3 | disaggregating access to effective treatment from broader lifestyle changes
409 IV, 11. 1. 4 | the same thing as equal treatment or utilization (Mooney et
410 IV, 11. 1. 5 | the extent to which the treatment corresponds to the needs
411 IV, 11. 1. 5 | may reduce disparities in treatment across physicians as well
412 IV, 11. 1. 5 | developed to facilitate drug treatment decision-making by clinicians (
413 IV, 11. 1. 5 | are based on results of treatment as opposed to the treatment
414 IV, 11. 1. 5 | treatment as opposed to the treatment levels themselves. Examples
415 IV, 11. 1. 5 | simple ignorance, lapses in treatment delivery, miscommunication,
416 IV, 11. 1. 6 | flat sum for a patient’s treatment according to their specific
417 IV, 11. 1. 6 | minimize costs within a treatment group (Busse et al, 2006).~ ~
418 IV, 11. 1. 6 | about outlier cases (i.e. treatment episodes with much higher
419 IV, 11. 2. 1 | curing illness and providing treatment of injury). There seems
420 IV, 11. 2. 1 | addition to diagnosis and treatment. Similarly, the Chronic
421 IV, 11. 5. 1 | the most cost-effective treatment for end-stage renal failure,
422 IV, 11. 5. 1 | it is the only available treatment. About 250.000 individuals
423 IV, 11. 5. 1 | future may offer practical treatment for other unmet medical
424 IV, 11. 5. 6 | and blood used in medical treatment. EU Directives have been
425 IV, 11. 6. 2 | cost are unable to obtain treatment, cannot access the same
426 IV, 11. 6. 4 | Best practice and latest treatment methods for diseases and
427 IV, 11. 6. 5 | clinical guidelines in the treatment of diabetes mellitus in
428 IV, 12. 1 | would otherwise have gone on treatment and burdened the economy.
429 IV, 12. 2 | the CVD risk increases; treatment targets for LDL cholesterol
430 IV, 12. 2 | life-long pharmacological treatment with drugs must be considered.~ ~
431 IV, 12. 2 | early detection, diagnosis, treatment and follow-up, and palliative
432 IV, 12. 2 | prevention, screening and treatment of the disease in Europe.~ ~
433 IV, 12. 2 | too advanced for curative treatment, thus improving the quality
434 IV, 12. 2 | diagnosis, access to optimal treatment and investment in health
435 IV, 12. 2 | early diagnosis, adequate treatment and end of life care. It
436 IV, 12. 2 | obtained through intensive treatment from diagnosis onwards.
437 IV, 12. 2 | intervention (early intensive treatment) can modify the progression.
438 IV, 12. 2 | timely initiation of adequate treatment. The WHO 2003 report defines
439 IV, 12. 2 | phases of tobacco addiction treatment, not only as a first-line
440 IV, 12. 2 | wide range of psychosocial treatment options, including counseling
441 IV, 12. 2 | licensed premises.~ ~Advice and treatment~ ~Healthcare-based interventions
442 IV, 12. 2 | wide variety of specialized treatment approaches have been evaluated,
443 IV, 12. 2 | than those not receiving treatment. Further, for the average
444 IV, 12. 2 | Genomics, mechanism and treatment of addiction~http European
445 IV, 12. 3 | an easy access to medical treatment when travelling, social
446 IV, 12. 3 | coverage abroad, more equal treatment of women and men, fight
447 IV, 12. 4 | research on health and treatment including public health
448 IV, 12. 10 | population through screening, treatment and rehabilitation of concrete
449 IV, 12. 10 | selected conditions and their treatment is offered by the Institute
450 IV, 12. 10 | of the Working~Group on Treatment of Under 18~year olds Presenting
451 IV, 12. 10 | year olds Presenting to Treatment~Services with Serious Drug
452 IV, 12. 10 | Ireland - Evaluating Drug Treatment Effectiveness) study.~ ~
453 IV, 12. 10 | care”~High~The National Treatment Purchase Fund (NTPF) which
454 IV, 12. 10 | and screening through to treatment services, supportive and
455 IV, 12. 10 | Enforcement for the equal treatment of men and women, concerning
456 IV, 12. 10 | prevention, diagnosis and treatment of mental and affective
457 IV, 12. 10 | Circular letter on diagnosis, treatment and control of AHT (Arterial
458 IV, 12. 10 | dead and needing medical treatment) in different environments~
459 IV, 13. 4 | implementing the principle of equal treatment between persons irrespective
460 IV, 13. 4 | general framework for equal treatment in employment and occupation.~
461 IV, 13. 5 | be required for hospital treatment abroad and must be given
462 IV, 13. 7 | become a common and effective treatment for end-stage renal, liver,
463 IV, 13. 7. 5 | the provision of care or treatment or the management of health
464 IV, 13. 7. 5 | the provision of care or treatment or the management of health-care
465 IV, 13. 9 | Incentives and Regulations in the Treatment of Ageing-related Diseases,
